Clinical trials: Blepharoptosis
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
This study will test whether XAF5 (XOPH5) ointment, applied once daily to the lower eyelids for 10 weeks, reduces the prominence of lower eyelid fat in adults with moderate to severe steatoblepharon (excess eyelid fat).
- Trial name
- NCT02230761
- Testing
- XOPH5 Ointment
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Topokine Therapeutics, Inc.
Blepharoptosis
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.
- Trial name
- NCT01848041
- Testing
- RVL-1201
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Acquired Blepharoptosis
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an…
- Trial name
- NCT02436759
- Testing
- RVL-1201
- Where
- 14 sites in United States
- Volunteers
- 140 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Acquired Blepharoptosis
LEV102 Topical Gel in Acquired Blepharoptosis
Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.
- Trial name
- NCT05715346
- Testing
- LEV102 1.0%, LEV102 2.0%, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Levation Pharma, Ltd.
Blepharoptosis
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03536949
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 35 sites in United States
- Volunteers
- 234 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Blepharoptosis
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03565887
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 36 sites in United States
- Volunteers
- 164 people
- Sponsor
- RVL Pharmaceuticals, Inc.